Abstract Library

#3090 Retrospective Experience with Pherochromocytoma (PH) and Paraganglioma (PG) in a Single Argentinian Institution

Introduction: Pherochromocytoma (PH) and paraganglioma (PG) are neuroendocrine tumors arising in cromaffin cells in the adrenal medulla or extra adrenal paraganglia respectively. Clinical presentation is diverse. All PG/PH have malignant potential. Hereditary cases comprise up to 40% of all PG/PH.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Dioca M, Calabretta M, Iglesias L, Rojas Bilbao E, Califano I,

Keywords: Pherochromocytoma and paraganglioma (PG),

#3079 Novel Symptoms and Therapy of Multiple Endocrine Neoplasia Type 1

Introduction: MEN1 is a rare autosomal inherited disease with hallmark of hyperparathyroidism, duodenopancreatic NENs and pituitary tumor.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: bai J

Authors: Bai J, Tang Q,

Keywords: MEN1, LGCS, NENs, gastrinoma, Parathyroid carcinoma,

#2972 Characteristics and Management of Paragangliomas, 10 Years Experience

Introduction: Paraganglioma (PG) is a rare extra-adrenal neuroendocrine tumor, with common sites of presentation being abdomen, and head and neck region. The majority of PGs appear to be sporadic. However, almost half of cases are associated with an inherited syndrome. The highest malignancy rates are seen in paragangliomas (PGs) associated with SDHB mutations, which are usually abdominal and secretory.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Sardo E, Cameselle-Garcia S, Casteras A, Toledo R, Acosta D,

Keywords: Paraganglioma, SDHB mutations, Functioning Tumors,

#2914 Safety Profile and Adverse Events of Special Interest for Surufatinib in Chinese Patients with Advanced Extra-Pancreatic Neuroendocrine Tumors: Analysis of the Phase 3 SANET-ep Trial

Introduction: The previously reported SANET-ep trial (NCT02588170) demonstrated surufatinib significantly improves progression-free survival (PFS) in patients (pts) with advanced extrapancreatic neuroendocrine tumors (epNETs) compared to placebo; median PFS (9.2 vs. 3.8 months; HR = 0.334, 95% CI 0.223 to 0.499, p<0.0001).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Li J

Authors: Li J, Xu J, Zhou Z, Bai C, Chi Y,

Keywords: extra-pancreatic, neuroendocrine tumors, safety,

#2833 Surgical Correction of Carcinoid Heart Disease Improves Liver Function and 5-Hydroxyindoleacetic Acid Levels

Introduction: Neuroendocrine tumours of the gastrointestinal tract cause carcinoid syndrome and carcinoid heart disease. These tumours secrete serotonin, which can bind to heart valves and cause fibrosis and valve incompetence. Most cases involve the tricuspid valve +/- pulmonary valve. Medical management comprises diuretics for fluid overload and somatostatin analogues to reduce circulating serotonin. Definitive treatment is heart-valve replacement surgery which improves exercise tolerance but has high perioperative mortality. We have previously reported that valve-replacement surgery can reduce 5-hydroxyindoleacetic acid (5-HIAA) levels, reflecting a decline in hormone activity.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Shah H

Authors: Shah H, Sagar V, Venkataraman H, Steeds R, Rooney S,

Keywords: carcinoid, carcinoid syndrome, neuroendocrine tumour, carcinoid heart disease, 5hiaa,